Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Cross-Sectional Study

Analysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy

Author(s): Paolo Mongiello*, Raffaele Petti, Andrea Ciaccia, Maria Grazia Morgese and Renato Lombardi

Volume 23, Issue 2, 2023

Published on: 26 September, 2023

Page: [111 - 121] Pages: 11

DOI: 10.2174/1871529X23666230810094738

Price: $65

Abstract

Introduction: Hypercholesterolemia is one of the main risk factors associated with atherosclerotic cardiovascular disease and coronary heart disease. Statins are the standard cholesterollowering treatment; however, they have shown, in clinical practice, a reduced adherence to therapy (<50%) and a modest achievement of the expected outcomes for treatment. This condition prompt scientific research to develop drugs with different mechanisms of action. In this regard, excellent results have been achieved with therapeutic use of monoclonal antibodies against PCSK9, enzyme involved in recycling of Low density lipoprotein receptors (LDLR) on the hepatocytes surface. Indeed, the reduction in receptor density caused by PCSK9 is associated with increased serum LDL levels.

Materials and Methods: After the data extraction of all Local Health Authority (ASL) of Foggia patients (302) who received, in 2021, at least one administration of Alirocumab or Evolocumab, the therapeutic adherence was calculated, for each individual patient, by indirect method (calculation of the Medication Possession Ratio - MPR). According to scientific literature, patients were classified into: adherents (MPR>80%), average adherents (MPR between 40% and 80%) and non-adherents (MPR<40%). Patients were then stratified by gender and age groups (0-18, 19-49, 50-64, >65).

Results: The results show that, for both drugs (Alirocumab and Evolocumab), women are more adherent than men and the group of young adults (19-49 years old) is the one with the lowest adherence to therapy, 69% for Alirocumab and 56% for Evolocumab.

Conclusion: According to Italian Drug Agency (AIFA), poor therapeutic adherence is the main cause of ineffectiveness of drug therapies, and it is associated with increased hospitalizations, morbidity and mortality. Data obtained from this study allow to detect the categories of patients who need specific programs about the correct use of drugs, in order to increase therapeutic adherence and facilitate the achievement of the expected outcomes for treatment.

« Previous Next »
Graphical Abstract

[1]
Ogura, M. PCSK9 inhibition in the management of familial hypercholesterolemia. J. Cardiol., 2018, 71(1), 1-7.
[http://dx.doi.org/10.1016/j.jjcc.2017.07.002] [PMID: 28784313]
[2]
Garret, RH; Grisham, CM Principi di Biochimica. Casa editrice PICCIN. 2004.
[3]
Rosenson, R.S.; Robert, A.H.; Sergio, F.; Christopher, P.C. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329.
[http://dx.doi.org/10.1016/j.jacc.2018.04.054]
[4]
Yurtseven, E.; Ural, D.; Baysal, K.; Tokgözoğlu, L. An Update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb., 2020, 27(9), 909-918.
[http://dx.doi.org/10.5551/jat.55400] [PMID: 32713931]
[5]
Sobati, S.; Shakouri, A.; Edalati, M.; Mohammadnejad, D.; Parvan, R.; Masoumi, J.; Abdolalizadeh, J. PCSK9: A key target for the treatment of cardiovascular disease (CVD). Adv. Pharm. Bull., 2020, 10(4), 502-511.
[http://dx.doi.org/10.34172/apb.2020.062] [PMID: 33062601]
[6]
OsMed Report 2013, the use of drugs in Italy. 2020. Available from: https://www.salute.gov.it/portale/medicinaliStupefacenti/dettaglioNotizieMedicinaliStupefacenti.jsp?lingua=italiano&menu=notizie&p=dalministero&id=1656
[7]
Barale, C.; Melchionda, E.; Morotti, A.; Russo, I. PCSK9 biology and its role in atherothrombosis. Int. J. Mol. Sci., 2021, 22(11), 5880.
[http://dx.doi.org/10.3390/ijms22115880] [PMID: 34070931]
[8]
Grundy, S.M.; Cleeman, J.I.; Merz, C.N.B.; Brewer, H.B., Jr; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C., Jr; Stone, N.J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation., 2004, 110(2), 227-239.
[http://dx.doi.org/10.1161/01.CIR.0000133317.49796.0E] [PMID: 15249516]
[9]
Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; Simes, J.; Collins, R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet., 2010, 376(9753), 1670-1681.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[10]
Silverman, M.G.; Ference, B.A. Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA., 2016, 316(12), 1289-1297.
[http://dx.doi.org/10.1001/jama.2016.13985] [PMID: 27673306]
[11]
Xia, X.; Peng, Z.; Gu, H.; Wang, M.; Wang, G.; Zhang, D. Regulation of PCSK9 expression and function: Mechanisms and therapeutic implications. Front. Cardiovasc. Med., 2021, 8, 764038.
[http://dx.doi.org/10.3389/fcvm.2021.764038] [PMID: 34782856]
[12]
Lemstra, M.; Blackburn, D.; Crawley, A.; Fung, R. Proportion and risk indicators of nonadherence to statin therapy: A meta-analysis. Can. J. Cardiol., 2012, 28(5), 574-580.
[http://dx.doi.org/10.1016/j.cjca.2012.05.007] [PMID: 22884278]
[13]
Mancini, G.B.J.; Baker, S.; Bergeron, J.; Fitchett, D.; Frohlich, J.; Genest, J.; Gupta, M.; Hegele, R.A.; Ng, D.; Pearson, G.J.; Pope, J.; Tashakkor, A.Y. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can. J. Cardiol., 2016, 32(S7), S35-S65.
[http://dx.doi.org/10.1016/j.cjca.2016.01.003] [PMID: 27342697]
[14]
Kasichayanula, S.; Grover, A.; Emery, M.G.; Gibbs, M.A.; Somaratne, R.; Wasserman, S.M.; Gibbs, J.P. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin. Pharmacokinet., 2018, 57(7), 769-779.
[http://dx.doi.org/10.1007/s40262-017-0620-7] [PMID: 29353350]
[15]
Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34(2), 154-156.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]
[16]
Sundararaman, S.S.; Döring, Y.; van der Vorst, E.P.C. PCSK9: A multi-faceted protein that is involved in cardiovascular biology. Biomedicines., 2021, 9(7), 793.
[http://dx.doi.org/10.3390/biomedicines9070793] [PMID: 34356856]
[17]
Gencer, B.; Lambert, G.; Mach, F. PCSK9 inhibitors. Swiss Med. Wkly., 2015, 145, w14094.
[PMID: 25856746]
[18]
Leblond, F.; Seidah, N.G.; Précourt, L.P.; Delvin, E.; Dominguez, M.; Levy, E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver. Physiol., 2009, 296(4), G805-G815.
[http://dx.doi.org/10.1152/ajpgi.90424.2008] [PMID: 19179626]
[19]
Luquero, A.; Badimon, L.; Borrell-Pages, M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front. Cardiovasc. Med., 2021, 8, 639727.
[http://dx.doi.org/10.3389/fcvm.2021.639727] [PMID: 33834043]
[20]
Langhi, C.; Le May, C.; Gmyr, V.; Vandewalle, B.; Kerr-Conte, J.; Krempf, M.; Pattou, F.; Costet, P.; Cariou, B. PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion. Biochem. Biophys. Res. Commun., 2009, 390(4), 1288-1293.
[http://dx.doi.org/10.1016/j.bbrc.2009.10.138] [PMID: 19878649]
[21]
Rohrbach, S.; Li, L.; Novoyatleva, T.; Niemann, B.; Knapp, F.; Molenda, N.; Schulz, R. Impact of PCSK9 on CTRP9-induced metabolic effects in adult rat cardiomyocytes. Front. Physiol., 2021, 12, 593862.
[http://dx.doi.org/10.3389/fphys.2021.593862] [PMID: 33643060]
[22]
Artunc, F. Kidney-derived PCSK9—a new driver of hyperlipidemia in nephrotic syndrome? Kidney Int., 2020, 98(6), 1393-1395.
[http://dx.doi.org/10.1016/j.kint.2020.07.027] [PMID: 33276863]
[23]
O’Connell, E.M.; Lohoff, F.W. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders. Front. Neurosci., 2020, 14, 609.
[http://dx.doi.org/10.3389/fnins.2020.00609] [PMID: 32595449]
[24]
Filardi, P.P.; Paolillo, S.; Trimarco, B. Lipid control in patients at high cardiovascular risk: Focus on PCSK9 inhibition. G. Ital. Cardiol., 2015, 16(1), 44-51.
[PMID: 25689751]
[25]
Seidah, N.G.; Prat, A. The multifaceted biology of PCSK9. Endocr. Rev., 2022, 43(3), 558-582.
[http://dx.doi.org/10.1210/endrev/bnab035] [PMID: 35552680]
[26]
Kaddoura, R.; Orabi, B.; Salam, A. PCSK9 monoclonal antibodies: An overview. Heart Views, 2020, 21(2), 97-103.
[http://dx.doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_20_20] [PMID: 33014302]
[27]
Summary of Product Characteristics (SPC) Evolocumab Available from: www.ema.europa.eu/en/documents/product-information/repatha-ep ar-product-information_it.pdf
[28]
Summary of Product Characteristics (SPC) Alirocumab Available from: www.ema.europa.eu/en/documents/product-information/praluent-e par-product-information_it.pdf
[29]
Adherence to Long-Term Therapies Evidence for Action; World Health Organization: Geneva, Switzerland, 2003.
[30]
Chávez-García, L.; Valle-Leal, J.G.; Jiménez-Mapula, C.; Quintero-Medrano, S.M.; López-Villegas, M.N. Therapeutic adherence and glycemic control in patients with gestational diabetes under two treatment schemes. Rev. Med. Chil., 2019, 147(5), 574-578.
[http://dx.doi.org/10.4067/S0034-98872019000500574] [PMID: 31859889]
[31]
Oscalices, M.I.L.; Okuno, M.F.P.; Lopes, M.C.B.T.; Campanharo, C.R.V.; Batista, R.E.A. Discharge guidance and telephone follow-up in the therapeutic adherence of heart failure: Randomized clinical trial. Rev. Lat. Am. Enfermagem, 2019, 27, e3159.
[http://dx.doi.org/10.1590/1518-8345.2484.3159] [PMID: 31432915]
[32]
Cramer, J.A.; Roy, A.; Burrell, A.; Fairchild, C.J.; Fuldeore, M.J.; Ollendorf, D.A.; Wong, P.K. Medication compliance and persistence: Terminology and definitions. Value. Health., 2008, 11(1), 44-47.
[http://dx.doi.org/10.1111/j.1524-4733.2007.00213.x] [PMID: 18237359]
[33]
Volpe, M.; Degli Esposti, L.; Romeo, F.; Trimarco, B.; Bovenzi, F.M.; Mastromarino, V.; Battistoni, A. The role of drug treatment adherence in the chronic therapy of cardiovascular disease: an inter-society consensus document. G. Ital. Cardiol., 2014, 15(10), 3S-10S.
[PMID: 25426833]
[34]
Volpe, M Prevention Italy 2021 – An update of the Consensus document and recommendations for cardiovascular prevention in Italy. G. Ital. Cardiol., 2021, 22(1), 5.
[35]
Dall'AIFA online il Rapporto nazionale 2021. “L'Uso dei Farmaci in Italia" 2021. Available from: https://www.epicentro.iss.it/farmaci/aggiornamenti
[36]
Mancusi, L.; Misericordia, P.; Polistena, B.; Spandonaro, F. I problemi di aderenza alle terapie in campo cardiovascolare. Ital. J.of Public Health, 2019, 8(6) Available from: https://www.quotidianosanita.it/allegati/allegato5482551.pdf
[37]
Jia, X.; Al Rifai, M.; Saeed, A.; Ballantyne, C.M.; Virani, S.S. PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance. Vasc. Health Risk Manag., 2022, 18, 555-566.
[http://dx.doi.org/10.2147/VHRM.S275739] [PMID: 35898405]
[38]
Zafrir, B.; Aya, E.; Nili, S.; Avishay, E.; Walid, S. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin. Lipidol., 2021, 15(1), P202-211.E2.
[39]
Saborowski, M.; Dölle, M.; Manns, M.P.; Leitolf, H.; Zender, S. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort. Cardiol. J., 2018, 25(1), 32-41.
[http://dx.doi.org/10.5603/CJ.a2017.0137] [PMID: 29168543]
[40]
Rolnick, S.J.; Pawloski, P.A.; Hedblom, B.D.; Asche, S.E.; Bruzek, R.J. Patient characteristics associated with medication adherence. Clin. Med. Res., 2013, 11(2), 54-65.
[http://dx.doi.org/10.3121/cmr.2013.1113] [PMID: 23580788]
[41]
Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.; Tokgozoglu, L.; Wiklund, O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J., 2019, 41(1), 111-188.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy